BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Geoffroy K, Bourgeois-Daigneault MC. The pros and cons of interferons for oncolytic virotherapy. Cytokine Growth Factor Rev 2020;56:49-58. [PMID: 32694051 DOI: 10.1016/j.cytogfr.2020.07.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Li Q, Tan F, Wang Y, Liu X, Kong X, Meng J, Yang L, Cen S. The gamble between oncolytic virus therapy and IFN. Front Immunol 2022;13:971674. [DOI: 10.3389/fimmu.2022.971674] [Reference Citation Analysis]
2 Cerqueira OLD, Antunes F, Assis NG, Cardoso EC, Clavijo-salomón MA, Domingues AC, Tessarollo NG, Strauss BE. Perspectives for Combining Viral Oncolysis With Additional Immunotherapies for the Treatment of Melanoma. Front Mol Biosci 2022;9:777775. [DOI: 10.3389/fmolb.2022.777775] [Reference Citation Analysis]
3 Musella M, Galassi C, Manduca N, Sistigu A. The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation. Biology (Basel) 2021;10:856. [PMID: 34571733 DOI: 10.3390/biology10090856] [Cited by in F6Publishing: 4] [Reference Citation Analysis]